RxDoctor Payments Data

John Stack

Physician Assistant · Oroville, CANPI 1629170592

Payments from drug & device makers

$2,203in general payments, 2019–2025

Across 117 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$818
  • Novo Nordisk$183
  • Lilly USA, LLC$168
  • AstraZeneca$136
  • GSK$134
  • Boehringer Ingelheim$123
  • plus $641 from 14 others

What the payments were for

  • Food & beverage$2,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,203 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin188$206,546
Trelegy ElliptaFluticasone/Umeclidin/Vilanter140$97,970
TrulicityDulaglutide103$95,611
OzempicSemaglutide73$86,149
RybelsusSemaglutide78$78,564
EliquisApixaban62$60,047
JanuviaSitagliptin Phosphate66$48,732
Combivent RespimatIpratropium/Albuterol Sulfate56$33,275
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$29,713
XareltoRivaroxaban18$27,219
VraylarCariprazine Hcl17$24,183
VascepaIcosapent Ethyl35$17,519
Tresiba Flextouch U-200Insulin Degludec13$14,996
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$11,062
FarxigaDapagliflozin Propanediol11$10,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$123$239,820244 claims
Novo NordiskOzempic, Rybelsus$183$164,713151 claims
GSKTrelegy Ellipta, Breo Ellipta$134$105,516159 claims
Lilly USA, LLCTrulicity$168$95,611103 claims
PfizerEliquis$38$60,04762 claims
MerckJanuvia, Belsomra$44$56,28784 claims
Johnson & JohnsonXarelto$86$27,21918 claims
AbbVieVraylar$818$24,18317 claims
AstraZenecaFarxiga$136$10,83711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Oroville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →